Full history for every metric is available with a Kvantra account
Lucira Health, Inc. (LHDX)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 93 | 212 |
| Operating profit | $m | -65 | -142 | |||||
| Net profit | $m | - | - | -7 | -9 | -37 | -65 | -143 |
| EPS reported | $ | -1.86 | -3.57 | |||||
| Operating cashflow per share | $ | -2.90 | -2.90 | |||||
| Capex per share | $ | 0.44 | 0.44 | |||||
| FCF per share | $ | -3.34 | -3.34 | |||||
| Free cash flow | $m | -116 | -108 | |||||
| Net debt | $m | -103 | -10 | |||||
| Book value equity | $m | 189 | 61 | |||||
| Book value per share | $ | 5.43 | 1.51 | |||||
| Number of shares | m | 34.77 | 40.22 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.59 | 0.30 | |||||
| P/S LTM | x | 3.22 | 0.09 | |||||
| P/FCF LTM | x | -2.57 | -0.17 | |||||
| EV/EBITDA LTM | x | -3.24 | -0.06 | |||||
| EV/Sales LTM | x | 2.11 | 0.04 | |||||
| Earnings Yield LTM | % | -21.66% | -412.23% | |||||
| FCF Yield | % | -38.84% | -590.13% | |||||
| Quality | ||||||||
| ROE | % | -34.34% | -102.50% | |||||
| ROIC | % | -33.68% | -33.68% | |||||
| Operating margin | % | -69.36% | -69.36% | |||||
| Gross margin | % | 10.99% | 10.99% | |||||
| FCF/Sales | % | -124.95% | -124.95% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | +558.80% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -41.10 | -2.25 | |||||
| Net Debt/EBITDA | x | 1.70 | 1.70 | |||||
| EBIT/Net interest | x | -21,513.33 | -21,513.33 | |||||
| Net debt/market cap | % | -34.46% | -56.45% | |||||
| Net debt/Equity | x | -0.55 | -0.17 | |||||
| Gross debt/equity | x | 0.01 | 0.79 | |||||
Company overview
Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lucira Health, Inc. (LHDX)
Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free